LEUKOTRIENE D4

Leukotriene D₄ (LTD₄) is an active metabolite of LTC₄ (Item Nos. 20210 | 10007241) and a constituent of slow-reacting substance of anaphylaxis (SRS-A). It is formed via metabolism of LTC₄ by γ-glutamyl transpeptidase. Like LTC₄, LTD₄ (0.01-0.1 pM) induces contractions in isolated guinea pig parenchymal strips and tracheal spirals. In vivo, LTD₄ increases insufflation pressure, a marker of bronchoconstriction, in anesthetized guinea pigs by 100% when administered at a dose of 89 pmol per animal. It also increases vascular permeability in guinea pig skin when administered intradermally at a dose of 0.1 pmol per animal.

LTD4 (Leukotriene D4) is a member of the leukotriene family shown to be a potent contractor of smooth muscle.

ChEBI: A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).

Slow reacting substance of anaphylaxis (SRS-A). Potent bronchoconstrictor and mediator of asthmatic and inflammatory processes. Increases cytosolic free Ca2+ in epithelial cells.

Human Endogenous Metabolite

[1] L ORNING  B S  S Hammarstrm. Leukotriene D: a slow reacting substance from rat basophilic leukemia cells.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77 4: 2014-2017. DOI: 10.1073/pnas.77.4.2014
[2] S HAMMARSTRM  K B  L Orning. Metabolism of leukotrienes.[J]. Molecular and Cellular Biochemistry, 1985, 69 1: 7-16. DOI: 10.1007/bf00225922
[3] PER HEDQVIST. Biological profile of Ieukotrienes C4 and D4[J]. Acta Physiologica, 1980, 110 3: 331-333. DOI: 10.1111/j.1748-1716.1980.tb06676.x
[4] EMILIE CERAUDO. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.[J]. The Journal of Biological Chemistry, 2021: 100163. DOI: 10.1074/jbc.ra120.015352
[5] ERICK LU. S-Geranylgeranyl-l-glutathione is a ligand for human B cell-confinement receptor P2RY8[J]. Nature, 2019, 567 7747: 244-248. DOI: 10.1038/s41586-019-1003-z
[6] NATHAN C NI. A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice.[J]. Journal of Pharmacology and Experimental Therapeutics, 2011, 339 3: 768-778. DOI: 10.1124/jpet.111.186031
[7] HAI-YAN QI. A cytosolic phospholipase A2-initiated lipid mediator pathway induces autophagy in macrophages.[J]. Journal of immunology, 2011, 187 10: 5286-5292. DOI: 10.4049/jimmunol.1004004
[8] E. ONO. Concentration of 14,15-leukotriene C4 (eoxin C4) in bronchoalveolar lavage fluid[J]. Clinical and Experimental Allergy, 2009, 39 9: 1348-1352. DOI: 10.1111/j.1365-2222.2009.03261.x
[9] PEDRO P MEDINA  Montse S C  Montse Sanchez Cespedes. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.[J]. Epigenetics, 2008, 3 2: 64-68. DOI: 10.4161/epi.3.2.6153
[10] KARSTEN GRONERT. Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses[J]. American Journal of Pathology, 2001, 158 1: Pages 3-9. DOI: 10.1016/s0002-9440(10)63937-5